Interní Med. 2008; 10(6): 273-276
We review the current knowledge in ACE-inhibitors and angiotensin II receptor 1 blockers in patients with coronary heart disease. The data from clinical trials in hypertension revealed some advantages of ACE-inhibitors, however results of direct comparison of large multicentric trial ONTARGET confirms the assumption that both pharmaceutical groups are effective, safe and comparable, but the combination of ACE-inhibitors and AII antagonists is probably not advisable. The blockade of system renin-angiotensin-aldosteron is a base of treatment of patients in secondary prevention of coronary heart disease. Only further studies will show on what level it is the most advantageous to block the whole system.
Published: July 1, 2008 Show citation